Usefulness of ketogenic diet in a girl with migrating partial seizures in infancy

Tatsuo Mori1, Katsumi Imai1, Taikan Oboshi1

  • 1National Epilepsy Center, NHO, Shizuoka Institute of Epilepsy and Neurological Disorders, Japan.

Brain & Development
|January 21, 2016
PubMed

Insights

Migrating partial seizures in infancy (MPSI), a severe epilepsy syndrome, can be effectively managed with a ketogenic diet when antiepileptic drugs fail. This case report highlights the diet

Area of Science:

  • Pediatric Neurology
  • Epilepsy Syndromes
  • Metabolic Therapies

Background:

  • Migrating partial seizures in infancy (MPSI) is an age-specific epilepsy characterized by intractable focal seizures and severe developmental delay.
  • Standard antiepileptic drugs (AEDs) are often ineffective in managing MPSI.
  • The role of specific gene mutations, such as KCNT1, in MPSI treatment response is an area of ongoing research.

Observation:

  • A 2-month-old infant presented with migrating focal seizures, initially unresponsive to multiple AEDs.
  • The patient exhibited a heterozygous missense mutation in the KCNT1 gene.
  • Partial response was noted with potassium bromide, but adverse effects limited its use.

Findings:

  • Introduction of a ketogenic diet at 9 months of age led to significant improvement in seizure frequency and severity.
  • The ketogenic diet was well-tolerated, with no significant adverse effects reported.
  • This intervention allowed for the patient's discharge from the hospital.

Implications:

  • The ketogenic diet represents a promising therapeutic option for infants with MPSI refractory to AEDs.
  • Further research is needed to understand the differential treatment responses in MPSI patients with and without KCNT1 mutations.
  • Accumulating case reports is crucial for establishing evidence-based treatment guidelines for MPSI.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
943
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.1K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K